Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.

Lactate dehydrogenase, creatinine kinase predict survival, poor prognosis in lung cancer

12 Sep 2017

Similar to their role in other cancers, plasma concentrations of lactate dehydrogenase (LDH) and creatinine kinase (CK) are independent predictors of survival and poor prognosis in lung cancer patients, particularly those with adenocarcinoma, a new study reveals.

The study included 1,142 lung cancer patients (69.2 percent male), of which 678 were positive for CK and 464 were negative, with respect to cut-off values. In comparison, 410 were LDH positive and 732 were negative.

In lung adenocarcinoma patients (n=608), bone metastasis was significantly more common in CK-negative than in CK-positive patients (27.6 vs 19.4 percent; p<0.05), while a stage four disease was significantly more common in in LDH-positive than in LDH-negative patients (72.5 vs 57.2 percent; p<0.05).

Elevated LDH levels were also significantly associated with metastasis to the bone (p<0.001), liver (p<0.001) and adrenal gland (p<0.001).

On the other hand, squamous cell carcinoma patients (n=307) that were positive for CK showed lower bone metastasis compared to those who were negative (6.8 vs 16.8 percent). Metastasis to other regions was not related to CK levels. LDH level was not significantly associated with any of the clinical characteristics.

In all lung cancer patients, lower plasma CK was associated with significantly poorer overall survival status (p<0.001), while higher LDH levels were linked to significantly poorer outcomes (p<0.001).

In those with adenocarcinoma, lower CH and higher LDH were associated with poor survival status (p<0.001 for both), while in squamous cell carcinoma patients, only CK concentration was tied to survival (p<0.05).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Mar 2016
The Drug Control Authority (DCA) of Malaysia has approved a new indication for the long-acting somatostatin analogue lanreotide. This new indication is for the treatment of grade 1 and low grade 2 gastroenteropancreatic neuroendocrine tumours (GEP-NETs)—of midgut, pancreatic or unknown origin except the hindgut—in adult patients with unresectable locally advanced or metastatic disease.